A Phase 2 interventional study of AX 250 in Mucopolysaccharidosis Type IIIB and MPS III B, sponsored by Allievex Corporation. Status unknown at 8 sites in 7 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Allievex Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.
Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 10th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2018, is one of 4 in phase 2, and was the 23rd registered.
58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.
Browse Mucopolysaccharidosis III studies →12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Sites in United States
Ages 4+
Ozlem Goker-Alpan · Sites in United States
Ages 18–99
Phoenix Nest · Sites in United States, France
Ages 12 mo+
Denali Therapeutics Inc. · Sites in United States
Ages 0–18
Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Sites in United States
Ages 5–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is above the median of 12 across 33 interventional studies indexed under Mucopolysaccharidosis III.
Median enrollment 17 across the 23 interventional studies, 30 across the 19 observational. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 43 have an industry lead sponsor. The 10 most frequent:
Allievex Corporation is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Allievex Corporation has 5 studies filed under Mucopolysaccharidosis III — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucopolysaccharidosis III with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06333041Phase 3Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterStudy of Cannabidiol in Sanfilippo Syndrome | 2027-04 |
| NCT04360265Phase 3Ultragenyx Pharmaceutical IncFollow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA | 2027-08 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06567769GC Biopharma CorpPhase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | 2027-06 |
| NCT05492799Allievex CorporationSafety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Mucopolysaccharidosis III with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the long-term safety and tolerability of AX 250 administered to subjects with MPS IIIB by an implanted ICV reservoir and catheter and to evaluate the impact of long-term AX 250 treatment on cognitive function in patients with MPS IIIB as assessed by developmental quotient (DQ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
Drug: AX 250
Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
Evaluate the Long-term safety and tolerability of AX 250 administered in up to 33 subjects with MPS IIIB by assessing the number of participants with abnormal clinical laboratory values and/or Adverse Events related to the treatment
Time frame: Entire study period, up to 240 weeks
Evaluating the impact of long-term AX 250 treatment on cognitive function in up to 33 patients with MPS IIIB as assessed by developmental quotient (DQ)
Time frame: Entire study period, up to 240 weeks
Evaluate the impact of long-term AX 250 treatment on cognitive function in up to 33 patients with MPS IIIB as assessed by age equivalent score (AEq)
Age equivalent score is derived from neurocognitive tests (Bayley Scales of Infant Development, 3rd edition OR Kaufman Assessment battery for Children, 2nd edition)
Time frame: Entire study period, up to 240 weeks
Characterize immunogenicity as measured by IgE levels, formation of anti-AX 250, IGF1 and IGF2 antibodies in Cerebrospinal fluid (CSF) and serum.
Time frame: Entire study period, up to 240 weeks
Evaluate the impact of long-term AX 250 treatment on Heparan sulfate (HS) levels in cerebrospinal fluid (CSF), serum and urine.
Time frame: Entire study period, up to 240 weeks
Evaluate the impact of long-term AX 250 treatment on brain structure assessed by magnetic resonance imaging (MRI)
Time frame: Entire study period, up to 240 weeks
Evaluate the impact of long-term AX 250 treatment on adaptive function derived from the Vineland Adaptive Behavior Scales, 2nd edition (VABS-II)
VABS-II is a measure of adaptive behavior and can be used to assess the level of subjects' functioning at various ages. Scale ranges from 0-4 (0 meaning never performs the behavior, and 4 meaning almost always performs the behavior independently)
Time frame: Entire study period, up to 240 weeks
Started Feb 2018 (actual). Primary completion is estimated for Jan 2025, 83 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tralesinidase alfa
Allievex Corporation